Reduced starting dose of TKI is comparable to a full dose in metastatic kidney cancer
A study published in the Journal of Hematology Oncology Pharmacy [...]
Age-based outcomes in kidney cancer patients treated with first-line targeted therapy or immunotherapy
This study compared disease outcomes, treatments, and dose reductions in [...]
Targeted therapy dose reduction resulted in better clinical outcomes
A recent post hoc analysis of the results from the [...]
